It is well known that histological transformation to SCLC is a known mechanism of resistance in 3–14% of patients with epidermal growth factor receptor (EGFR) mutations receiving EGFR tyrosine kinase inhibitors (EGFR-TKIs) (9–11). The gene discussed is EGFR; the disease is small cell lung carcinoma.